AzTrials
AzTrials

Anxiety DisordersNCT03907917

Transcranial Direct Current Stimulation and Fear Extinction

A study testing tDCS in people with Anxiety Disorders, run by Thomas Adams at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Psychiatric disorders characterized by pathological fear and anxiety are common and often disabling. Despite their limitations, exposure therapies are among the most efficacious treatments for these disorders. Extinction learning is thought to be a core mechanism of therapeutic exposure. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Anxiety Disorders
What is being tested?
tDCS
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
67 participants
Where
2 sitesUnited States
Study dates
9 Apr 2019to 1 Jun 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Ability to provide informed consent (as established by clinical interview), and voluntary, signed informed consent prior to the performance of any study-specific procedures;
  • Ability and willingness to perform study-relevant clinical assessments;
  • Ability and willingness to receive transcranial direct current stimulation (tDCS);
  • Ability and willingness to complete magnetic resonance imaging (MRI) scans;
  • Free of current psychiatric diagnosis;
  • Psychiatrically healthy;
  • 18-55 years of age;
  • Medication free or stable (> 4 weeks) medication(s).

Who cannot join

  • Any unstable medical, psychiatric, or neurological condition (including active or otherwise problematic suicidality) that may necessitate urgent treatment;
  • Any substance dependence or severe substance abuse within the past 6 months;
  • Daily use of psychotropic medications that substantially lower seizure threshold (e.g., clozapine);
  • Daily use of psychotropic drugs that may interfere with extinction learning (e.g., anxiolytics);
  • Any history of a psychotic disorder or of mania;
  • Current active suicidal ideation or any suicidal intent;
Show all 15Show fewer
  • Any major neurological disease or history of major head trauma, including concussion with extended loss of consciousness, or of psychosurgery;
  • Any history of epilepsy;
  • Pregnancy;
  • Any metal in the body or other contraindication to MRI scanning or tDCS;
  • Any history of adverse effects to brain stimulation;
  • A current Diagnostic and Statistical Manual diagnosis in the past 6 months, as determined by clinical interview;
  • History of a severe psychiatric disorder, either documented or by clinician judgment;
  • Use of drugs that are known to influence hemodynamic properties, except for drugs that are used to treat hypertension;
  • Severe claustrophobia, back pain, or other condition that may make an extended magnetic resonance scan difficult or lead to excessive movement during the scan.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • University of Kentucky

    Lexington, Kentucky, 40506

  • Yale School of Medicine

    New Haven, Connecticut, 06511

Other trials in United States

About this study

Official title: The Effects of Transcranial Direct Current Stimulation on Fear Extinction Learning and Memory Processes

Psychiatric disorders characterized by pathological fear and anxiety are common and often disabling. Despite their limitations, exposure therapies are among the most efficacious treatments for these disorders. Extinction learning is thought to be a core mechanism of therapeutic exposure. Extinction learning is mediated by a well-defined circuit encompassing the medial prefrontal cortex (mPFC), amygdala, and hippocampus. This raises the exciting possibility that direct engagement of this circuitry might enhance the response to therapeutic exposure. Transcranial direct current stimulation (tDCS) is a neuromodulation technology that can augment brain plasticity, learning, and memory. The proposed study will evaluate whether tDCS can engage extinction circuitry, and improve extinction learning and memory.

This study will enroll psychiatrically healthy volunteers to test whether tDCS applied to the mPFC can augment spontaneous mPFC activity, engagement of extinction circuitry during extinction learning and recall, and classically-conditioned extinction learning and memory. Healthy volunteers will complete a standardized, three-day fear conditioning and extinction learning and memory task. On day 1, participants will complete a fear conditioning task. On day 2, participants will receive sham (placebo) or active tDCS prior to completing a fear extinction learning task. On day 3, participants will complete an extinction recall task. Electrodermal activity and heart rate will be continuously monitored during the conditioning and extinction procedures to assess autonomic arousal. All procedures will be completed in a magnetic resonance imaging (MRI) scanner; imaging data will be collected before and after tDCS and during all conditioning and extinction procedures.

Read the detailed description

Most effective behavioral treatments of disordered anxiety involve repeated exposure to feared stimuli, which often results in systematic reductions in fearful responding to said stimuli. It is believed that this process results from successful fear extinction, a well-characterized learning process that is mediated by fear extinction brain circuitry. Namely, fear extinction is an inhibitory learning process that requires activation and plasticity within a variety of brain regions, including the medial prefrontal cortex (mPFC), which can exert inhibitory control over fearful responding and parts of the brain that drive said responding. Behavioral treatments of disordered anxiety, while effective, have serious limitations; many patients fail to respond at all or only partially respond to exposure-based treatments. One candidate reason for this is deficits in fear extinction learning or memory processes. The proposed study aims to examine the effects of non-invasive neuromodulation - namely, multifocal transcranial direct current stimulation (tDCS) targeting the mPFC - on spontaneous mPFC activity (Aim 1), functional activation of fear extinction circuitry (Aim 2), and fear extinction learning and memory (Aim 3).

This study will randomize 64 psychiatrically healthy volunteers at the Yale (proposed n = 32) and the University of Kentucky (proposed n = 32) for Aims 1-3. Following the completion of proper diagnostic and safety screening and Institutional Review Board (IRB) approved informed consent, healthy volunteers will complete a 3-day experimental procedure. Subjects will be conditioned to fear a previously neutral stimulus on Day 1. Subjects will be randomized (1:1, double-blind) to receive Active or Sham tDCS prior to fear extinction training on Day 2. Allocation will be done by independent research staff at Yale, who is experienced with such allocation, using block randomization (blocks of 8), stratified by sex. Subjects and investigators will be blind to allocation. Lastly, the strength of extinction recall will be tested on Day 3. Functional magnetic resonance imaging (fMRI) and psychophysiological measures (electrodermal activity and heart rate) will be acquired during all fear conditioning, extinction, and recall procedures and prior to and after tDCS.

tDCS will be delivered using an 8-channel Starstim transcranial electric stimulator from Neuroelectrics. To target the mPFC, the anodal electrode will be placed over the frontal pole (Fpz, 10-20 EEG landmarks) and will be surrounded by five return (cathodal) electrodes in a circumferential array (AF7, AF8, F3, Fz, and F4). Subjects in the Active tDCS condition will receive 20 minutes of direct current stimulation for 20 minutes; current will be ramped in and out for 30 seconds at the beginning and end of the 20-minute period. Subjects in the Sham tDCS condition will receive the same electrode placement and ramping procedures, but no current will be delivered between ramping.

All healthy volunteers will complete state-of-the-art Human Connectome Project Style (HCP-Style) accelerated multiband acquisition sequences. Scan sequences will be identical across sites. Scans will include a mixture of structural, resting state, and functional fMRI sequences. All scans will be completed on Siemens Prisma 3T scanners using 64-channel head coils. Psychophysiological measures will include electrodermal activity (EDA) and heart rate. All psychophysiological data will be collected with MRI-compatible Biopac systems.

Study 1 is well-powered for both planned and exploratory analyses; proposed methods help to improve signal-to-noise-ratio (SCR) and our proposed sample size of 64 will adequately power all a priori analyses, planned contrasts, and exploratory analyses. Power analysis suggested a sample of 42 would be adequate for the proposed primary hypothesis tests. We propose to recruit 70 participants to allow for approximately 10% attrition or data failures (e.g., head movement or null skin conductance response [SCR]). Our statistical approach and statistical power were developed in collaboration with statistical consultants of the PI and the primary mentor.

The proposed study will provide important preliminary data to examine the potential for medial prefrontal tDCS to augment and enhance fear extinction processes across multiple levels of analyses: the effects of tDCS on extinction circuitry and classically-conditioned extinction learning and memory.

Being tested
tDCS
Medical subject headings
Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tDCSDevice

    Also called transcranial direct current stimulation, transcranial electrical stimulation, Starstim®

    Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.

Study groups in NCT03907917
Study groupRoleWhat they receive
Active tDCSActive comparatorCurrent will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
Receives: Device: tDCS
Sham tDCSSham comparatorCurrent will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
Receives: Device: tDCS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fractional amplitude of low frequency fluctuations (fALFF)

    fALFF is a measure of resting brain activity that is derived by calculating regionally-specific fluctuations in Blood Oxygen Level-Dependent (BOLD) activation within a low-frequency band, typically while the participant is at rest.

    Measured: Immediately following administration of tDCS on day 2 of the protocol.

  2. Event related brain activation during extinction learning

    Blood Oxygen Level-Dependent imaging (BOLD imaging) will be measured during extinction training.

    Measured: BOLD imaging will be measured during extinction training on day 2 of the protocol.

  3. Event related brain activation during extinction recall

    Blood Oxygen Level-Dependent imaging (BOLD imaging) will be measured during extinction recall.

    Measured: BOLD imaging will be measured during the test of extinction recall on day 3 of the experimental protocol.

  4. Skin conductance response (SCR) during extinction learning

    SCR will be measured by collecting electrodermal activity (EDA) on the left hand and subtracting the maximal EDA value during the presentation of the virtual context (CX) picture from the maximal EDA value during the presentation of the conditioning stimuli (CS).

    Measured: SCR will be measured during extinction learning on day 2 of the experimental protocol.

  5. Skin conductance response (SCR) during extinction recall

    SCR will be measured by collecting electrodermal activity (EDA) on the left hand and subtracting the maximal EDA value during the presentation of the virtual context (CX) picture from the maximal EDA value during the presentation of the conditioning stimuli (CS).

    Measured: SCR will be measured during extinction recall on day 3 of the experimental protocol.

Secondary outcomes (3)
  1. Functional connectivity measure of tDCS

    Correlations between brain regions over the time course.

    Measured: Immediately prior to and following administration of tDCS. Change in connectivity from pre to post stimulation (delta) will be modeled and used as the dependent variable.

  2. Functional connectivity during extinction learning

    Correlations between brain regions over the time course

    Measured: During extinction learning on day 2 of the experimental protocol.

  3. Functional connectivity during extinction recall

    Correlations between brain regions over the time course

    Measured: During extinction recall on day 3 of the experimental protocol.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Apr 2019
  2. Study start9 Apr 2019
  3. Primary completion1 Jun 2023
  4. Study completion1 Jun 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
Subjects will be randomly assigned to receive Active (real) or Sham (placebo) transcranial direct current stimulation.
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
67 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03907917
Sponsor's protocol ID
1412015006_b
Other IDs
1K23MH111977
Status last verified
Aug 2023
First submitted
1 Apr 2019
Last updated
24 Aug 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Raw imaging and psychophysiological data will be freely available upon study publication. Data will be stored on a yet to be determined data sharing repository supported by the National Institutes of Health.

Questions about this trial

What is this clinical trial studying?

A study testing tDCS in people with Anxiety Disorders, run by Thomas Adams at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fractional amplitude of low frequency fluctuations (fALFF) (time frame: Immediately following administration of tDCS on day 2 of the protocol.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in